Genetico’s H1 2025 Results under Russian Accounting Standards

The GENETICO Center for Genetics and Reproductive Medicine (MOEX: GECO) published its performance results for the six months of 2025 prepared in compliance with the Russian Accounting Standards (RAS).

For the first six months of 2025, the Company's revenue increased by 56.3 % compared to the same period in 2024.

The Company fully repaid its issued bonds in June 2025, eliminating outstanding loan obligations.

The Genetico Center, a resident of Skolkovo and the Medtech Technopark, is part of Artgen Biotech Group (MOEX: ABIO). The company specializes in medical genetics and genetic research, implementing innovative solutions for the diagnostics, prevention, and treatment of genetic and socially significant diseases in healthcare practice.

Key highlights for the 6 months of 2025:

The number of studies conducted increased by 43%, and that of consultations by 22 % compared to the previous period.
Genetico received a patent for the Onconetix panel for genetic tumor research and targeted cancer therapy selection.
Genetico invested RUB 20 million in Retinostar, a developer of first-in-class gene therapy drugs for orphan eye diseases.
Genetico has fully repaid its RUB 145 million bond loan.
Genetico's shares are now listed on the St. Petersburg Stock Exchange, including in an additional session.
Genetico completed a private placement of 7 million shares in favor of Artgen Biotech Group companies.

Income Statement Key Highlights

in RUB thous.	January to June 2025	January to June 2024	Change, %, 2025/2024
Revenue	282 845	181 006	56,3%
Cost of sales	(214 963)	(131 401)	63,6%
Gross profit (loss)	67 882	49 605	36,8%
Commercial expenses	(32 386)	(24 389)	32,8%
Administrative expenses	(41 260)	(24 922)	65,6%
Profit (loss) on sales	(5 764)	294	-2 060,5%
Interest receivable	999	571	75,0%
Interest payable	(5 424)	(9 850)	-44,9%
Other net income (expenses)	1 042	292	256,8%
Net profit (loss)	(9 147)	(8 693)	-5,2%
EBITDA	21 579	12 555	71,9%
EBITDA, % of revenue	7,6%	6,9%	-

Balance sheet key highlights

in RUB thous.	June 30, 2025	December 31, 2024	Change, %, 2025/2024
ASSETS
Intangible assets + fixed assets	652 527	659 520	-1,1%
Inventories	129 502	118 628	9,2%
Accounts receivable	93 301	68 522	36,2%
Financial investments	30 500	30 500	0,0%
Cash and cash equivalents	35 298	3 571	888,5%
TOTAL ASSETS	941 309	881 002	6,8%
LIABILITIES
Capital and reserves	591 228	600 376	-1,5%
Non-current liabilities	40 447	45 101	-10,3%
Current liabilities	309 634	235 525	31,5%
TOTAL LIABILITIES	941 309	881 002	6,8%

The full H1 2025 financial statements of CGRM Genetico, PJSC, according to RAS are available through the link.

For additional information, please contact krasotkin@nextgene.ru.